Cannabinoid Receptor Changes in HIV-Positive Brains May Explain Cognitive Problems

Brain tissue analysis found that CB1 and CB2 receptors were differently expressed in people with HIV-associated cognitive disorders compared to those without, with CB1 levels correlating with memory and processing speed deficits.

Swinton, Mary K et al.·Viruses·2021·Preliminary EvidenceCross-Sectional
RTHC-03563Cross SectionalPreliminary Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Immunoblot analysis showed CB1 and CB2 receptors were differentially expressed in frontal cortices of HAND versus neurocognitively unimpaired HIV-positive brains. CB1 expression negatively correlated with memory and processing speed. In HAND brains, CB1 shifted from neuronal processes to cell bodies and showed increased colocalization with astrocytes.

Key Numbers

CB1 and CB2 differentially expressed in HAND vs NUI brains; CB1 expression negatively correlated with memory and information processing speed; CB1 redistributed from neuronal processes to soma in HAND; increased CB1 colocalization with astroglial marker in HAND.

How They Did This

Cross-sectional biochemical and immunohistochemical analyses of CB1 and CB2 receptor expression in post-mortem brain specimens from people with HIV, comparing those with and without HIV-associated neurocognitive disorders.

Why This Research Matters

With HIV-associated cognitive disorders persisting despite antiretroviral therapy, identifying endocannabinoid system changes could open new therapeutic targets for the estimated 50% of people with HIV who experience some degree of cognitive impairment.

The Bigger Picture

The redistribution of cannabinoid receptors in HIV-affected brains suggests that the endocannabinoid system is involved in the cognitive impairment that persists despite viral suppression, potentially explaining why some people with HIV report cognitive benefits from cannabis use.

What This Study Doesn't Tell Us

Post-mortem brain analysis cannot establish causation; small sample sizes; cross-sectional design; antiretroviral medication effects not fully controlled; cannot determine if receptor changes preceded or resulted from cognitive decline.

Questions This Raises

  • ?Could cannabinoid-based therapies improve cognitive function in people with HIV?
  • ?Does cannabis use by people with HIV normalize the receptor redistribution seen in HAND?

Trust & Context

Key Stat:
CB1 receptor levels negatively correlated with memory and processing speed in HIV-positive brains
Evidence Grade:
Post-mortem brain analysis providing preliminary evidence of endocannabinoid system involvement in HIV-associated cognitive disorders.
Study Age:
Published in 2021.
Original Title:
Alterations in Brain Cannabinoid Receptor Levels Are Associated with HIV-Associated Neurocognitive Disorders in the ART Era: Implications for Therapeutic Strategies Targeting the Endocannabinoid System.
Published In:
Viruses, 13(9) (2021)
Database ID:
RTHC-03563

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

How does HIV affect cannabinoid receptors in the brain?

In people with HIV-associated cognitive disorders, CB1 receptors were redistributed from their normal locations on neuronal connections to cell bodies and astrocytes, and their expression levels correlated with cognitive deficits.

Could cannabis help HIV-related cognitive problems?

The altered endocannabinoid system in HIV brains suggests it could be a therapeutic target, but this study examined brain tissue, not cannabis treatment. Clinical trials would be needed to determine if cannabinoid therapies could improve cognitive function.

Read More on RethinkTHC

Cite This Study

RTHC-03563·https://rethinkthc.com/research/RTHC-03563

APA

Swinton, Mary K; Sundermann, Erin E; Pedersen, Lauren; Nguyen, Jacques D; Grelotti, David J; Taffe, Michael A; Iudicello, Jennifer E; Fields, Jerel Adam. (2021). Alterations in Brain Cannabinoid Receptor Levels Are Associated with HIV-Associated Neurocognitive Disorders in the ART Era: Implications for Therapeutic Strategies Targeting the Endocannabinoid System.. Viruses, 13(9). https://doi.org/10.3390/v13091742

MLA

Swinton, Mary K, et al. "Alterations in Brain Cannabinoid Receptor Levels Are Associated with HIV-Associated Neurocognitive Disorders in the ART Era: Implications for Therapeutic Strategies Targeting the Endocannabinoid System.." Viruses, 2021. https://doi.org/10.3390/v13091742

RethinkTHC

RethinkTHC Research Database. "Alterations in Brain Cannabinoid Receptor Levels Are Associa..." RTHC-03563. Retrieved from https://rethinkthc.com/research/swinton-2021-alterations-in-brain-cannabinoid

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.